Home > Haematology > ASH 2021 > Lymphoma > POLARIX: Novel regimen superior to R-CHOP in DLBCL

POLARIX: Novel regimen superior to R-CHOP in DLBCL

Presented By
Prof. Hervé Tilly, University of Rouen, France
ASH 2021
Phase 3, POLARIX
Polatuzumab vedotin added to rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) outperformed the standard-of-care regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as initial treatment in patients with diffuse large B-cell lymphoma (DLBCL). The safety profiles of the 2 regimens were comparable [1]. Prof. Hervé Tilly (University of Rouen, France) explained that R-CHOP, the standard-of-care regimen for patients with DLBCL, is effective in 60–70% of patients with this condition. In the last 20 years, adaptations to the R-CHOP treatment regimen have not succeeded in meeting the unmet need in this population. The current, randomised, double-blind, phase 3 POLARIX trial (NCT03274492) added polatuzumab vedotin, an antibody drug conjugate targeting CD79b, to rituximab, cyclo...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on